Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/125358
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Baron, Ralf | - |
dc.contributor.author | Allegri, Massimo | - |
dc.contributor.author | Correa Illanes, Gerardo | - |
dc.contributor.author | Hans, Guy | - |
dc.contributor.author | Serpell, Michael | - |
dc.contributor.author | Mick, Gerard | - |
dc.contributor.author | Mayoral Rojals, Victor | - |
dc.date.accessioned | 2018-10-16T13:02:37Z | - |
dc.date.available | 2018-10-16T13:02:37Z | - |
dc.date.issued | 2016-12-01 | - |
dc.identifier.uri | http://hdl.handle.net/2445/125358 | - |
dc.description.abstract | When peripheral neuropathic pain affects a specific, clearly demarcated area of the body, it may be described as localized neuropathic pain (LNP). Examples include postherpetic neuralgia and painful diabetic neuropathy, as well as post-surgical and post-traumatic pain. These conditions may respond to topical treatment, i.e., pharmaceutical agents acting locally on the peripheral nervous system, and the topical route offers advantages over systemic administration. Notably, only a small fraction of the dose reaches the systemic circulation, thereby reducing the risk of systemic adverse effects, drug-drug interactions and overdose. From the patient's perspective, the analgesic agent is easily applied to the most painful area(s). The 5% lidocaine-medicated plaster has been used for several years to treat LNP and is registered in approximately 50 countries. Many clinical guidelines recommend this treatment modality as a first-line option for treating LNP, particularly in frail and/or elderly patients and those receiving multiple medications, because the benefit-to-risk ratios are far better than those of systemic analgesics. However, some guidelines make only a weak recommendation for its use. This paper considers the positioning of the 5% lidocaine-medicated plaster in international treatment guidelines and how they may be influenced by the specific criteria used in developing them, such as the methodology employed by randomized, placebo-controlled trials. It then examines the body of evidence supporting use of the plaster in some prevalent LNP conditions. Common themes that emerge from clinical studies are: (1) the excellent tolerability and safety of the plaster, which can increase patients' adherence to treatment, (2) continued efficacy over long-term treatment, and (3) significant reduction in the size of the painful area. On this basis, it is felt that the 5% lidocaine-medicated plaster should be more strongly recommended for treating LNP, either as one component of a multimodal approach or as monotherapy. | - |
dc.format.extent | 21 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Springer | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1007/s40122-016-0060-3 | - |
dc.relation.ispartof | Pain and Therapy, 2016, vol. 5, num. 2, p. 149-169 | - |
dc.relation.uri | https://doi.org/10.1007/s40122-016-0060-3 | - |
dc.rights | cc by (c) Baron et al., 2016 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | - |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Dolor | - |
dc.subject.classification | Malalties del sistema nerviós | - |
dc.subject.other | Pain | - |
dc.subject.other | Nervous system Diseases | - |
dc.title | The 5% Lidocaine-medicated Plaster: Its Inclusion In International Treatment Guidelines For Treating Localized Neuropathic Pain, and Clinical Evidence Supporting Its Use | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2018-07-24T12:15:14Z | - |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/633491/EU//DOLORisk | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 27822619 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Publicacions de projectes de recerca finançats per la UE |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
BaronR.pdf | 601.81 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License